Novartis announced in early September that pelacarsen, a drug designed to lower lipoprotein(a), did not reduce cardiovascular events such as heart attacks, strokes and emergency bypass surgery in patients with existing heart disease. The Lp(a)HORIZON trial had tested whether an 80%-plus reduction in Lp(a) levels would translate into fewer clinical events, but the company has not explained why the trial failed, and did not respond to requests for comment.
nature.com
· 2026-11-03
Novartis has agreed to license a drug from Chinese biotech Abogen in a deal valued at up to $7.8 billion. Abogen describes its lead drug as having the potential to transform treatment for patients with autoimmune diseases.
wsj.com
· 2026-10-02
Legend Biotech has appointed Ingrid Zhang, an executive from Novartis, as its new chief executive officer. She fills a leadership vacancy that opened in July after the company's previous CEO resigned abruptly.
wsj.com
· 2026-09-15
Novartis and Bristol Myers Squibb have both suspended clinical trials of experimental autoimmune therapies after participants died or suffered life-threatening reactions. The companies are now investigating what caused the treatments, once seen as promising, to turn dangerous.
wsj.com
· 2026-09-03
Novartis suspended eight clinical trials testing a cell therapy for autoimmune and neurological conditions after three participants died in late August. The company has not disclosed the cause of death or which specific therapy is affected beyond confirming the pause across all related studies.
wsj.com
· 2026-09-01
GoKawiil